Rosuvastatin
Rosuvastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet and exercise, in adults with hypercholesterolemia.
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 301542; UNII 83MVU38M7Q. The label names the substance as rosuvastatin calcium, so UNII 83MVU38M7Q is the UNII of the salt form and is a broad match. MeSH lists this substance under entry terms and not as its own descriptor, so no MeSH identifier is recorded. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Aurobindo Pharma Limited label for rosuvastatin tablets (rosuvastatin calcium), application ANDA079170, effective 2026-08-28 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 59 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 59
- Phase 3 or 4
- 54
- Recruiting
- 3
- Regulatory decisions
- 0
| Phase | Recruiting | Active, not recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 0 | 0 | 4 | 0 | 1 | 5 |
| Phase 3 | 2 | 0 | 21 | 1 | 2 | 26 |
| Phase 4 | 1 | 2 | 9 | 1 | 15 | 28 |
| All phases | 3 | 2 | 34 | 2 | 18 | 59 |
Conditions these trials study
- Dyslipidemia
- High cholesterol (hypercholesterolemia)
- Coronary artery disease
- Acute coronary syndrome
- Hypertension (high blood pressure)
- Stroke
- Atherosclerosis
- Diabetes mellitus
- Heart attack (myocardial infarction)
- Arrhythmia (heart rhythm problems)
Sponsors with the most trials
- Sanofi
- University of Roma La Sapienza
- Korea University Anam Hospital
- AstraZeneca
- Centro Cardiopatici Toscani
About this drug
- Level
- Substance
- Mechanism
- Not reported
Classification codes
-
83MVU38M7Q
Claims and evidence
Context People for whom the US label of rosuvastatin lists an indication: adults with hypercholesterolemia
- Recipient
- Adult
- Population
- Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the passage read states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with hypercholesterolemia
- Excluded
- None stated
The US label of rosuvastatin tablets (rosuvastatin calcium), in the Aurobindo Pharma Limited version dated 2026-08-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet and exercise, in adults with hypercholesterolemia.
Applies to Adult People for whom the US label of rosuvastatin lists an indication: adults with hypercholesterolemia
- Certainty method
- Not assessed
- Limitations
- This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-07
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- The label sentence that gives the LDL-cholesterol indication.
- Retrieved
- Source effective date
- 2026-08-28
- Source state
- Current
- Version fingerprint
6da0a125e34c70cb18a1f2635bbbd5e50c08af3707b52f5663be3660eb0dafc0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260828.
- Retrieved
- Source effective date
- 2026-08-28
- Source state
- Current
- Version fingerprint
6da0a125e34c70cb18a1f2635bbbd5e50c08af3707b52f5663be3660eb0dafc0- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists lowering LDL cholesterol as an indication: High cholesterol (hypercholesterolemia)
Applies to Adult People for whom the US label of rosuvastatin lists an indication: adults with hypercholesterolemia
The US label of rosuvastatin tablets (rosuvastatin calcium), in the Aurobindo Pharma Limited version dated 2026-08-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet and exercise, in adults with hypercholesterolemia.Limitations. This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry trials 59
Record details
- Record id
cardio:rosuvastatin- Content hash
e86a518f40e0fa702b18db0bf1ec7c8d5c17e0fdb8f67e0422a91fe2d7def3e0